Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
- 3 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (2), 222-227
- https://doi.org/10.1038/s41591-019-0747-1
Abstract
Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir1,2. Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy3. However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8+ T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption4. Increased CD4+ T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.Funding Information
- Fonds de Recherche du Québec - Santé
- Gouvernement du Canada | Canadian Institutes of Health Research (15977, 15049, 152536, 152977)
- U.S. Department of Health & Human Services | National Institutes of Health (AI144462, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, AI126620, 1P30AI124414-01A1, 1P30AI124414-01A1, R01AI-129795, AI-144462)
- Einstein-Rockefeller-CUNY Center for AIDS Research
- Bill and Melinda Gates Foundation (OPP1092074, OPP1124068)
This publication has 33 references indexed in Scilit:
- Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost VaccinationJournal of Virology, 2010
- Ex vivo T cell–based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responsesNature Protocols, 2010
- The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infectionThe Journal of Experimental Medicine, 2009
- Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and SequencingJournal of Virology, 2008
- Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of TherapyThe Journal of Infectious Diseases, 2008
- Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnoverThe Journal of Experimental Medicine, 2007
- Clustal W and Clustal X version 2.0Bioinformatics, 2007
- High Levels of HIV-1 in Plasma During All Stages of Infection Determined By Competitive PCRScience, 1993
- The Role of Mononuclear Phagocytes in HTLV-III/LAV InfectionScience, 1986
- Similarities among retrovirus proteinsNature, 1984